Articles related to CANNABIS/MARIJUANA

The US Department of Health and Human Services’ (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) issued the 2021 National Survey on Drug Use and Health (NSDUH) this week. The NDSUH offers a window into Americans’ experiences with mental health disorders, substance use, and their pursuit of treatment during the second year of the COVID epidemic through chosen estimates by race, ethnicity, and age group. Enough said—the outcomes aren’t appealing.

The American Journal of Psychiatry presents this review of the most compelling articles that were covered in 2022: The Molecular and Cellular Alterations That Underpin Psychiatric Illnesses Shared and Distinct Neurobiological Mechanisms of PTSD Cognitive Deficits in Long-Term Cannabis Users Longitudinal Outcomes of Duration of Untreated Psychosis Accelerating TMS in the Treatment of Depression Infant Brain Development, Fragile X Syndrome, and Autism Spectrum Disorder Combining Computational Modeling and Postmortem Human Brain Studies to Uncover Synaptic Variability Contributions to Cortical Gamma Oscillation From the AJP Residents’ Journal: Identity and Stigma

This brief editorial introduces a series of articles describing the medical use of hallucinogens, ketamine, marijuana, and other agents — including the legal and ethical perspectives — in the treatment of various neurologic and psychiatric disorders.

A multi-variate analysis published in Cancer Medicine, which includes a population of more than 150,000 individuals, suggests that prior cannabis use was associated with a reduced risk of renal cell carcinoma and bladder cancer in women and prostate cancer in men. A potentially conflicting finding was increased risk of some cancers in current cannabis users.

Treatment resistance affects nearly half of all young people experiencing moderate-to-severe anxiety. In this 12-week open-label trial, patients received add-on CBD after noclinical improvement on therapy with CBT and/or antidepressant medication. There wasa more than 40% reduction in mean OASIS scores and no serious or unexpectedadverse events.

The review, which we covered previously, concluded that “oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation.”